VFA
SRPT icon

Virtus Fund Advisers’s Sarepta Therapeutics SRPT Stock Holding History

Virtus Fund Advisers’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$1.29M Buy
23,150
+19,577
+548% +$1.04M 0.01% 271
2017
Q3 		$162K Buy
+3,573
New +$143K ﹤0.01% 382
2014
Q3 		– Sell
-3,471
Closed -$103K – 1833
2014
Q2 		$103K Buy
+3,471
New +$110K ﹤0.01% 1378

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Virtus Fund Advisers's SRPT Position: Q4 2017 in Review

Virtus Fund Advisers increased its Sarepta Therapeutics (SRPT) stake by 548% in Q4 2017, buying an estimated $1.04M and bringing the position to 23,150 shares worth $1.29M. The position accounts for 0.01% of the portfolio, ranked #271.

Virtus Fund Advisers first reported a position in SRPT in Q2 2014 and has held it in 3 quarters since. 254 funds tracked by Wall St. Rank hold SRPT as of Q4 2017.

  • Virtus Fund Advisers held 23,150 shares of Sarepta Therapeutics worth $1.29M as of Q4 2017.
  • Virtus Fund Advisers bought 19,577 Sarepta Therapeutics shares in Q4 2017, an estimated $1.04M.
  • Sarepta Therapeutics made up 0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #271 holding.
  • Virtus Fund Advisers first reported a position in Sarepta Therapeutics in Q2 2014 and has held it in 3 quarters since.
  • 254 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.